登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>B7-1 >B71-H82F2

Biotinylated Human B7-1 / CD80 Protein, Fc,Avitag™ (MALS verified)

热销产品推荐:

利用生物素-链霉亲和素系统的高特异性和高灵敏度的结合特性,可将生物素化蛋白与链霉亲和素相关产品联合应用于各类实验,与非生物素体系相比,检测速度更快、结合能力更强、非特异背景更低。

分子别名(Synonym)

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

表达区间及表达系统(Source)

Biotinylated Human B7-1, Fc,Avitag (B71-H82F2) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # NP_005182.1).

Predicted N-terminus: Val 35

Request for sequence

蛋白结构(Molecular Characterization)

Online(Val 35 - Asn 242) NP_005182.1

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 52.3 kDa. As a result of glycosylation, the protein migrates as 65-95 kDa under reducing (R) condition, and 130-160 kDa under non-reducing (NR) condition (SDS-PAGE).

标记(Biotinylation)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Biotin:Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>95% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) SDS-PAGE gel

Biotinylated Human B7-1, Fc,Avitag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS

Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) MALS images

The purity of Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) is more than 85% and the molecular weight of this protein is around 130-165 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

Biotinylated Human ELISA

Immobilized Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) at 5 μg/mL (100 μL/well) can bind Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) with a linear range of 0.6-9.8 ng/mL (QC tested).

Protocol

Biotinylated Human  ELISA

Immobilized Human PD-L1, Fc Tag (Cat. No. PD1-H5258) at 10 μg/mL (100 μL/well) can bind Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) with a linear range of 0.156-5 μg/mL (Routinely tested).

Protocol

Biotinylated Human ELISA

Serial dilutions of Ipilimumab were added into Human CTLA-4, Fc Tag (Cat. No. CT4-H5255): Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) binding reactions. The half maximal inhibitory concentration (IC50) is 0.8260 μg/mL (Routinely tested).

Protocol

活性(Bioactivity)-FACS

Biotinylated Human FACS

Flow Cytometry assay shows that Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 0.3 μg/mL (Routinely tested).

Protocol

Biotinylated Human FACS

FACS analysis shows that the binding of Biotinylated Human B7-1, Fc,Avitag (Cat. No. B71-H82F2) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-Human CTLA-4 antibody. The concentration of B7-1 used is 0.3 μg/mL. The IC50 is 3.025 μg/mL (Routinely tested).

Protocol

 

背景(Background)

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

 

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
B7-1靶点信息
英文全称:Cluster of differentiation 80
中文全称:分化群80
种类:Homo sapiens
上市药物数量:2详情
临床药物数量:6详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定